Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in GILD — Gilead Sciences, Inc.

CIK 1423053 MIAMI, FL
Back to GILD Full portfolio

Position in GILD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$554,997,122
+$77,842,918 QoQ
Shares Held
3,982,185
+2.4% QoQ
Ownership
0.321%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in GILD Over Time

Shares Held

Position Value (USD)

Derivatives in GILD

reported options exposure · as of Mar 31, 2026
CallValue
$206,434,844
CallShares
1,481,200
PutValue
$83,663,811
PutShares
600,300

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $2,757,631,879 across 16 Drug Manufacturers - General names. GILD ranks #1 (20.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 GILD
Gilead Sciences, Inc.
This page 		3,982,185 $554,997,122
2 JNJ
Johnson & Johnson
 1,930,976 $472,007,773
3 MRK
Merck & Co., Inc.
 3,821,227 $459,655,395
4 AZN
Astrazeneca PLC
 1,869,793 $368,760,574
5 LLY
ELI LILLY & Co
 241,714 $222,321,285
6 PFE
Pfizer Inc
 7,359,865 $206,665,008
7 ABBV
AbbVie Inc.
 490,285 $106,632,084
8 NVO
Novo Nordisk A S
 2,736,525 $100,567,293

All Filings in GILD

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $206,434,844 1,481,200
2026-03-31 $83,663,811 600,300
2026-03-31 $554,997,122 3,982,185
2025-12-31 $477,154,204 3,887,520
2025-12-31 $138,757,570 1,130,500
2025-12-31 $127,551,408 1,039,200
2025-09-30 $136,585,500 1,230,500
2025-09-30 $127,294,800 1,146,800
2025-09-30 $578,050,926 5,207,666
2025-06-30 $179,953,097 1,623,100
2025-06-30 $606,519,324 5,470,545
2025-06-30 $171,471,542 1,546,600
2025-03-31 $116,016,570 1,035,400
2025-03-31 $138,236,085 1,233,700
2025-03-31 $602,152,441 5,373,962
2024-12-31 $433,759,266 4,695,889
2024-12-31 $71,051,004 769,200
2024-12-31 $128,135,664 1,387,200
2024-09-30 $109,780,096 1,309,400
2024-09-30 $420,701,825 5,017,913
2024-09-30 $100,180,416 1,194,900
2024-06-30 $105,913,257 1,543,700
2024-06-30 $78,469,257 1,143,700
2024-06-30 $19,100,132 278,387
2024-03-31 $389,814,084 5,321,694
2024-03-31 $116,987,575 1,597,100
2024-03-31 $64,848,225 885,300
2023-12-31 $32,501,535 401,204
2023-12-31 $84,760,763 1,046,300
2023-12-31 $98,621,574 1,217,400
2023-09-30 $98,770,920 1,318,000
2023-09-30 $29,370,184 391,916
2023-09-30 $106,961,862 1,427,300
2023-06-30 $80,121,972 1,039,600
2023-06-30 $121,801,428 1,580,400
2023-06-30 $23,033,602 298,866
2023-03-31 $91,233,812 1,099,600
2023-03-31 $120,812,617 1,456,100
2023-03-31 $186,825,125 2,251,719
2022-12-31 $141,781,275 1,651,500
2022-12-31 $184,148,250 2,145,000
2022-12-31 $142,083,037 1,655,015
2022-09-30 $172,084,255 2,789,500
2022-09-30 $21,063,864 341,447
2022-09-30 $115,736,609 1,876,100
2022-06-30 $130,653,978 2,113,800
2022-06-30 $221,032,560 3,576,000
2022-06-30 $193,261,758 3,126,707
2022-03-31 $198,390,595 3,337,100
2022-03-31 $145,607,138 2,449,237

Report a Problem

Category
Description
Email (optional, for follow-up)